martedì, 4 ottobre 2022
26 Ottobre 2017

DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval

October 24, 2017 – The non–Hodgkin lymphoma landscape recently underwent a major transformation, as researchers in the field saw the FDA approval of axicabtagene ciloleucel (axi-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for transplant-ineligible patients with relapsed or refractory disease. The approval was specifically for patients with large B-cell lymphoma following 2 prior therapies, including those with diffuse large B-cell lymphoma (DLBCL) … (leggi tutto)